U-47700 is a structural isomer of the earlier opioid [[AH-7921]]<ref>{{cite journal|first1=R. T.|last1=Brittain|first2=D. N.|last2=Kellett|first3=M. L.|last3=Neat|first4=R.|last4=Stables|title=Proceedings: Anti-nociceptive effects in ''N''-substituted cyclohexylmethylbenzamides.|journal=British Journal of Pharmacology|date=September 1973|issn=0007-1188|pages=158P–159P|volume=49|issue=1|pmid=4207044|pmc=1776456|doi=10.1111/j.1476-5381.1973.tb08279.x}}</ref> and the result of a great deal of work elucidating the [[quantitative structure–activity relationship]] of the scaffold. Upjohn looked for the key [[moiety (chemistry)|moieties]] which gave the greatest activity<ref>{{cite book|first1=Erik T.|last1=Michalson|first2=Jacob|last2=Szmuszkovicz|title=Medicinal agents incorporating the 1,2-diamine functionality|url=https://link.springer.com/chapter/10.1007/978-3-0348-9146-2_6|publisher=Birkhäuser Basel|journal=Progress in Drug Research|date=1989|isbn=9783034891462|pages=135–149|series=Progress in Drug Research|doi=10.1007/978-3-0348-9146-2_6|pmid=2687936}}</ref> and posted over a dozen patents on related compounds, each optimizing one moiety<ref>{{cite web | url=https://patents.google.com/patent/US3258489 | title=Patent US US3258489 - N-(1-aminocyclohexylmethyl)anilines and N-(1-nitrocyclohexylmethyl)anilines | date=28 June 1966 | author=Darrell D. Mullins}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3975443 | title=Patent US3975443 - 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine | date=17 August 1976 | author1=Norman James Harper | author2=George Bryan Austin Veitch}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3499033 | title=Patent US3499033 - Ethers of α-phenyl-2-aminocycloalkanemethanols | date=3 March 1970 | author=Jacob Szmuszkovicz Kalamazoo}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3510492 | title=Patent US3510492 - 2-anilino and 2-anilinomethyl cycloalkylamines | date=5 May 1970 | author=Jacob Szmuszkovicz}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3647804 | title=Patent US3647804 - Cycloalkanecarboxamides | date=7 March 1972 | author1=Ronald H. Rynbrandt | author2=Louis L. Skaletzky}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3825595 | title=Patent US3825595 - N-cyclopentyl-N-2-hydroxyalkyl-ring-substituted benzamides | date=23 July 1974 | author=W. Roll}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US4049663 | title=Patent US4049663 - Ethylene diamine derivatives | date=20 September 1977 | author1=Norman James Harper | author2=George Bryan Austin Veitch}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US4463013 | title=Patent US4463013 - Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs | date=9 April 1982 | author1=Robert J. Collins | author2=Lester J. Kaplan | author3=James H. Ludens | author4=Philip F. Von Voigtlander}}</ref> until they discovered that U-47700 was the most active.<ref>{{cite book|first1=Alan F.|last1=Casy|first2=Robert T.|last2=Parfitt|title=Miscellaneous Groups of Analgesics|url=https://link.springer.com/chapter/10.1007/978-1-4899-0585-7_11|publisher=Springer US|journal=Opioid Analgesics|date=1986|isbn=9781489905857|pages=385–403|doi=10.1007/978-1-4899-0585-7_11}}</ref>

 
== Side effects ==

 
U-47700 has never been studied on humans, but would be expected to produce effects similar to those of other potent opioid agonists, including strong analgesia, sedation, euphoria, constipation, itching and respiratory depression which could be harmful or fatal.<ref>{{cite web | url=http://www.nbcdfw.com/news/local/New-Synthetic-Opioid-Surfaces-in-North-Texas-371528161.html | title=New Synthetic Opioid Surfaces in North Texas | publisher=NBCDFW | date=9 March 2016 | author=Todd L. Davis}}</ref><ref>{{cite journal|first1=Matthew J.|last1=Jones|first2=Bradley S.|last2=Hernandez|first3=Gregory C.|last3=Janis|first4=Samuel J.|last4=Stellpflug|title=A case of U-47700 overdose with laboratory confirmation and metabolite identification|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1209767|journal=Clinical Toxicology|date=2016|issn=1556-3650|pages=1–5|volume=55|issue=|pmid=27549165|doi=10.1080/15563650.2016.1209767}}</ref><ref>{{cite journal|first1=K.|last1=Domanski|first2=K. C.|last2=Kleinschmidt|first3=J. M.|last3=Schulte|first4=S.|last4=Fleming|title=Two cases of intoxication with new synthetic opioid, U-47700|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1209763|journal=Clinical Toxicology|date=2016|issn=1556-3650|pages=1–5|volume=55|issue=|pmid=27432224|doi=10.1080/15563650.2016.1209763|first5=C.|last5=Frazee|first6=A.|last6=Menendez|first7=K.|last7=Tavakoli}}</ref><ref>{{cite journal|first1=Xiulu|last1=Ruan|first2=Srinivas|last2=Chiravuri|first3=AlanD.|last3=Kaye|title=Comparing fatal cases involving U-47700|url=https://link.springer.com/article/10.1007/s12024-016-9795-8|journal=Forensic Science, Medicine, and Pathology|date=September 2016|issn=1547-769X|pages=369–371|volume=12|issue=3|doi=10.1007/s12024-016-9795-8|pmid=27421264}}</ref><ref>{{cite journal|first1=Simon P.|last1=Elliott|first2=Simon D.|last2=Brandt|first3=Christopher|last3=Smith|title=The first reported fatality associated with the synthetic opioid 3,4-dichloro-''N''-[2-(dimethylamino)cyclohexyl]-''N''-methylbenzamide (U-47700) and implications for forensic analysis|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1984/full|journal=Drug Testing and Analysis|date=August 2016|issn=1942-7611|pages=875–879|volume=8|issue=8|doi=10.1002/dta.1984|pmid=27232154}}</ref><ref>{{cite journal|first1=Patil|last1=Armenian|first2=Alexander|last2=Olson|first3=Andres|last3=Anaya|first4=Alicia|last4=Kurtz|title=Fentanyl and a Novel Synthetic Opioid U-47700 Masquerading as Street "Norco" in Central California: A Case Report|url=http://www.sciencedirect.com/science/article/pii/S019606441630292X|journal=Annals of Emergency Medicine|doi=10.1016/j.annemergmed.2016.06.014|pmid=27473610|first5=Rawnica|last5=Ruegner|first6=Roy R.|last6=Gerona|volume=69|pages=87–90}}</ref><ref>{{cite journal|first1=Anders|last1=Helander|first2=Matilda|last2=Bäckberg|title=New Psychoactive Substances (NPS) – the Hydra monster of recreational drugs|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1217003|journal=Clinical Toxicology|date=2016|issn=1556-3650|pmid=27549399|doi=10.1080/15563650.2016.1217003|pages=1–3}}</ref> Tolerance and dependence would be expected to develop.<ref>{{cite journal|first1=Andreas|last1=Kimergård|first2=Torben|last2=Breindahl|first3=Peter|last3=Hindersson|first4=Paolo|last4=Deluca|title=Tampering of opioid analgesics: a serious challenge for public health?|url=http://onlinelibrary.wiley.com/doi/10.1111/add.13436/full|journal=Addiction|date=October 2016|issn=1360-0443|pages=1701–1702|volume=111|issue=10|doi=10.1111/add.13436|pmid=27273814}}</ref>
